Scandinavian Biopharma expands its Nordic vaccine business with the oral typhoid vaccine Vivotif®

Pressmeddelande -

Scandinavian Biopharma expands its Nordic vaccine business with the oral typhoid vaccine Vivotif®

Scandinavian Biopharma has entered into a Nordic distribution agreement with Emergent Travel Health for the oral typhoid vaccine Vivotif®. Typhoid fever is a severe and potentially life-threatening infection caused by the Salmonella bacteria.

The Scandinavian Biopharma team is very experienced in marketing and sales of vaccines. Since 1st of January 2020 Scandinavian Biopharma is the local representative for Vivotif® in Sweden, Norway, Denmark and Finland.

Björn Sjöstrand, CEO of Scandinavian Biopharma comments, “We are really excited about our expanded collaboration with Emergent and to strengthen our vaccine portfolio with Vivotif®. This product perfectly supports our commitment to protect travellers from contracting serious diseases”.

For more information, please contact:Jonas Bengtsson, VP Business Development: +46 70 861 30 03, jonas@scandinavianbiopharma.se

Ämnen

Scandinavian Biopharma

We are a research-based specialty biopharma company determined to give people worldwide a longer and better life. We are developing the first vaccine for protection against diarrhoea caused by ETEC in both travellers and endemic populations. We distribute a wide range of specialty biopharma products with focus on vaccines and immunoglobulins. 

www.scandinavianbiopharma.se

Kontakter

Björn Sjöstrand

Björn Sjöstrand

Presskontakt VD +46 (0)72 712 51 20

Relaterat innehåll

During last year, the company hit a new sales record for the distribution business. The sales increased from 51,3 MSEK in 2017 to 81,3 MSEK in 2018, representing an increase of 58%!

Scandinavian Biopharma announces great progress in the development of ETVAX® as well as a strong organic growth for the distribution business

Scandinavian Biopharma can look back on a very successful 2018! The company was granted 7,4 MEUR from EDCTP for testing the protective efficacy of the ETEC vaccine candidate ETVAX® in children below five years of age in Low- and Middle-Income Countries. The distribution business achieved a very strong organic sales growth of 58%.

Sales distribution business 2011-2019

Scandinavian Biopharma is once again looking back on a very successful business year

The company was granted 10.6 MEUR from the EDCTP for a phase III trial of the ETEC vaccine candidate ETVAX® in children in Low- and Middle-Income Countries. Impressive clinical results from Phase I/II study in Bangladesh were published. A late phase African paediatric development program was initiated. The distribution business continued to grow, reaching new record of 84.1 MSEK (7.9 MEUR) 2019.

Revenue, Distribution Business 2011-2020

Scandinavian Biopharma shows strong financial results for the pandemic year 2020

​The year we have left behind us has been different in many ways. Despite the major impact the pandemic had on operations in 2020, Scandinavian Biopharma reports largely unchanged revenue for the distribution operations and important progress has been made in the development of the ETEC vaccine candidate ETVAX®.

Vi är ett forskningsbaserat biotechföretag fast beslutna att ge människor i hela världen ett längre och bättre liv.

Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.

Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.

www.scandinavianbiopharma.se

Vår information på mynewsdesk riktar sig till journalister och media.

Scandinavian biopharma
Industrivägen 1, vån 4
171 48 Solna
Sverige
Hemsida
LinkedIn-sida